Key facts
- It has raised $610K; the latest was Seed Round ($610K) in Jul 2025.
- Notable investors include Encomenda, Ona Capital, Radia Accelerator, Roberto Urbez.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Metly
- ·The full record, as it builds
Funding rounds
No funding rounds for Metly are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Metly
Developer of a pharmaceutical business development platform designed to facilitate licensing and manufacturing partnerships. The company's platform aggregates regulatory data, market signals, and a broad catalog of products and verified partners, supports tailored recommendations based on portfolio needs, and centralizes communication workflows, enabling pharmaceutical business development teams to identify strategic opportunities, accelerate product launches, and streamline partner engagement.
- Sector
- Information Technology
- HQ
- Barcelona, Spain
- Founded
- 2024
- Employees
- 2
- Website
- metly.ai/
- Ownership
- Privately Held (backing)
Metly doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metly shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metly in its N-PORT filings yet. We sweep new filings monthly.